The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030
RootsAnalysishas done a detailed study on TargetedProtein Degradation Market: Focus on Therapeutics and Technology Platforms(based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags,IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein HomeostaticModulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors),2020-2030,covering key aspects of the industry’s evolution and identifying potentialfuture growth opportunities.
Toorder this 330+ page report, which features 130+ figures and 145+ tables,please visit this TargetedProtein Degradation Market: Focus on Therapeutics and Technology Platforms(based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags,IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein HomeostaticModulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors),2020-2030
Key Market Insights
§ More than 85 small molecule protein degraders are currentlybeing evaluated for the treatment of various disease indications; in addition,there are 25+ technology platforms available for use in therapy developmentefforts
§ The pipeline features a variety of candidate drugs thattarget a wide range of disease-causing / associated proteins; majority of theexisting drug candidates are designed for administration via non-invasive routes
§ Although start-ups and mid-sized firms are spearheading theinnovation, several big pharmaceutical companies are also engaged in thisdomain
§ Close to 5,500 patients were estimated to have beenenrolled in clinical trials worldwide, evaluating a number of relevantpre-marketing end points across various phases of development
§ A number of prominent scientists from renowned universities have emergedas key opinion leaders, owing to their active involvement in clinicaldevelopment efforts
§ Published scientific literature indicates that bothindustry and academic players have made equal contributions to the innovationin this field; the major focus of such studies is presently on PROTACs
§ Foreseeing a lucrative future, several private and publicinvestors have invested over USD 3.5 billion across close to 100 instances offunding since 2014
§ The increasing interest in this field is also reflected in recentpartnership activity; most of these deals are focused on novel technologyplatforms, involving the active participation of both international andindigenous companies
§ Short term opportunity in this market is likely to bedriven by licensing activity, depending on the capability of novel technologiesto meet protein degrader design and development needs
§ As multiple mid-late stage drug candidates are approved formarketing, the long term opportunity is likely to be distributed acrossdifferent types of protein degraders, target therapeutic areas and variousglobal regions
Formore information please visit:
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3.1. Contextand Background
3.2. Conceptof Protein Homeostasis
3.3. Discoveryof the Ubiquitin Proteasome System
3.3.1. Ubiquitin:Structure and Function
3.3.2. Fundamentalsof the UPS
3.3.3. Componentsof the UPS
3.4. KeySteps Involved in the UPS
3.4.1. Ubiquitination:The First Step
3.4.2. ProteasomalDegradation: The Second Step
3.5. TherapeuticApplications of the UPS
3.6. Advantagesand Challenges Associated with Ubiquitin Enzyme Inhibitors
3.7. Targeted Protein Degradation: EnhancingUbiquitination to Degrade Undruggable Targets
3.7.1. BriefHistory of Targeted Protein Degradation
3.8. Typesof Protein Degraders
3.8.1. SelectiveHormone Receptor Degraders (SHRDs)
3.8.2. ImmumodulatoryImide Drugs (IMiDs)
3.8.3. PROTACs
3.8.4. OtherChimeras (ENDTACs, LYTACs and PHOTACs)
3.8.4.1. Endosome Targeting Chimeras(ENDTACs)
3.8.4.2. Lysozyme targeting chimeras (LYTACs)
3.8.5. Specific and Nongenetic Inhibitor-of-ApoptosisProteins (IAP)-dependent Protein Erasers (SNIPERS)
3.8.6. HydrophobicTag
3.8.7. MolecularGlues
3.8.8. DUBInhibitors
3.9. GrowthDrivers and Roadblocks
4. CURRENTMARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeuticsand Technologies: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Type of Target Enzyme
4.2.6. Analysis by Type of Target Protein
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeuticsand Technologies: List of Research Tools / Key Technology Platforms
4.4. Targeted Protein Degradation-based Therapeuticsand Technologies: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Location of Headquarters
4.4.3. Analysis by Size of Company
4.4.4. Analysis by Type of Protein Degrader
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Clinical Candidates
5.2.1. Radius Health
5.2.1.1. Company Overview
5.2.1.2. Targeted Protein Degradation-basedDrug Portfolio
5.2.1.2.1. ProductDescription: Elacestrant
5.2.1.3. Recent Developments and FutureOutlook
5.2.2. Celgene
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Targeted Protein Degradation-basedDrug Portfolio
5.2.2.3.1. Avadomide(CC-122)
5.2.2.3.2. Iberdomide(CC-220)
5.2.2.4. Recent Developments and FutureOutlook
5.2.3. Sanofi Genzyme
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Targeted Protein Degradation-basedDrug Portfolio
5.2.3.3.1. ProductDescription: SAR439859
5.2.3.4. Recent Developments and FutureOutlook
5.3. Developers with Preclinical /Early-stage Clinical Candidates
5.3.1. Arvinas
5.3.2. Captor Therapeutics
5.3.3. Genentech
5.3.4. Kymera Therapeutics
5.3.5. Mission Therapeutics
5.3.6. Progenra
5.3.7. Zenopharm
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Targeted Protein Degradation-based Therapeuticsand Technologies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number ofClinical Trials
6.3.3. Geographical Analysis by EnrolledPatient Population
6.3.4. Analysis by Type of Protein Degrader
6.3.5. Analysis by Phase of Development
6.3.6. Analysis by Study Design
6.3.7. Analysis by Type of Sponsor /Collaborator
6.3.8. Most Active Players: Analysis byNumber of Registered Trials
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Therapeutic Area
6.3.11. Analysis by Clinical Endpoints
7. KOL ANALYSIS
7.1. ChapterOverview
7.2. Scopeand Methodology
7.3. Targeted Protein Degradation-based Therapeuticsand Technologies: List of Principal Investigators Involved in Clinical Trials
7.3.1. Analysisby Type of Organization
7.3.2. Analysisby Designation
7.3.3. GeographicalDistribution
7.3.4. Analysisby Therapeutic Focus
7.3.5. Analysisby Phase of Development and Type of Degrader
7.4. ProminentKey Opinion Leaders
7.5. KOL Benchmarking: Roots Analysisversus Third Party Scoring (ResearchGate Score)
7.6. MostActive Key Opinion Leaders
7.6.1. KOLProfile (Hagop Youssoufian)
7.6.2. KOLProfile (Patricia LoRusso)
7.6.3. KOLProfile (Johann De Bono)
7.6.4. KOLProfile (John N Nemunaitis)
7.6.5. KOLProfile (Robert Morgan)
7.6.6. KOLProfile (Edward O’Mara)
8. PUBLICATIONANALYSIS
8.1. ChapterOverview
8.2. Scopeand Methodology
8.3. Targeted Protein Degradation-Based Therapeuticsand Technologies: Recent Publications
8.3.1. Analysisby Year of Publication
8.3.2. Analysisby Study Objective
8.3.3. EmergingFocus Areas
8.3.4. Analysisby Type of Protein Degrader
8.3.5. Analysisby Target Protein
8.3.6. Analysisby Target Enzyme
8.3.7. Analysisby Target Indication
8.3.8. Analysisby Type of Publisher
8.3.9. LeadingPlayers: Analysis by Number of Publications
8.3.10. LeadingPlayers: Geographical Analysis by Number of Publications
8.3.11. KeyJournals: Analysis by Number of Publications
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Targeted Protein Degradation:Funding and Investment Analysis
9.3.1. Analysis by Number of FundingInstances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Investedacross Different Protein Degraders
9.3.5. Analysis by Number of Funding Instances and AmountInvested across Different Therapeutic Areas
9.3.6. Analysis by Amount Invested across Different ProteinDegradation Technology Platforms
9.3.7. Most Active Players: Analysis byNumber of Funding Instances
9.3.8. Most Active Investors: Analysis byNumber of Funding Instances
9.3.9. Geographical Analysis by AmountInvested
9.4. Concluding Remarks
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Targeted Protein Degradation-based Therapeutics andTechnologies: Recent Collaborations and Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Protein Degrader
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Different ProteinDegradation Technology
10.3.6. Most Active Players: Analysis byNumber of Partnerships
10.3.7. Geographical Analysis
10.3.7.1. MostActive Players: Regional Analysis by Number of Partnerships
10.3.7.2. Intercontinentaland Intracontinental Agreements
11. MARKET SIZING AND OPPORTUNITYANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and ForecastMethodology
11.3. Overall Targeted Protein Degradation-basedTherapeutics and Technologies Market, 2020-2030
11.3.1. Targeted Protein Degradation-based Therapeutics andTechnologies Market by Upfront Payments, 2020-2030
11.3.2. Targeted Protein Degradation-based Therapeutics andTechnologies Market by Milestone Payments, 2020-2030
11.3.3. Targeted Protein Degradation-based Therapeutics andTechnologies Market: Distribution by Type of Protein Degrader
11.3.3.1. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Degronimids, 2020-2030
11.3.3.2. Targeted Protein Degradation-based Therapeutics andTechnologies Market for PROTACs, 2020-2030
11.3.3.3. Targeted Protein Degradation-based Therapeutics andTechnologies Market for SARDs / SERDs, 2020-2030
11.3.3.4. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Specific BET and DUB Inhibitors, 2020-2030
11.3.3.5. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Other Protein Degraders, 2020-2030
11.3.4. Targeted Protein Degradation-based Therapeutics andTechnologies Market: Distribution by Therapeutic Area
11.3.4.1. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Neurodegenerative Disorders, 2020-2030
11.3.4.2. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Oncological Disorders, 2020-2030
11.3.4.3. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Other Therapeutic Areas, 2020-2030
11.3.5. Targeted Protein Degradation-based Therapeutics and TechnologiesMarket: Distribution by Route of Administration
11.3.5.1. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Oral Route, 2020-2030
11.3.5.2. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Intravenous Route, 2020-2030
11.3.5.3. Targeted Protein Degradation-based Therapeutics andTechnologies Market for Other Routes, 2020-2030
11.3.6. Targeted Protein Degradation-based Therapeutics andTechnologies Market: Distribution by Geography
11.3.6.1. Targeted Protein Degradation-based Therapeutics andTechnologies Market in North America, 2020-2030
11.3.6.2. Targeted Protein Degradation-based Therapeutics andTechnologies Market in Europe, 2020-2030
11.3.6.3. Targeted Protein Degradation-based Therapeutics andTechnologies Market in Asia-Pacific, 2020-2030
12. EXECUTIVEINSIGHTS
13. CONCLUDING REMARKS
13.1. ChapterOverview
13.2. KeyTakeaways
14. APPENDIX1: TABULATED DATA
15. APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
